<DOC>
	<DOCNO>NCT00754143</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability two dose regimen FG-3019 administer 12 week patient diabetic nephropathy proteinuria background angiotensin convert enzyme inhibitor ( ACEi ) and/or angiotensin II receptor antagonist ( ARB ) therapy .</brief_summary>
	<brief_title>Phase 1 Study FG-3019 Subjects With Type 1 Type 2 Diabetes Mellitus Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age 1880 year , inclusive 2 . Diagnosis type 1 type 2 diabetes accord American Diabetes Association ( ADA ) criteria 3 . First morning urinary ACR &gt; 0.200 g/g 4 . Receiving stable dos ACEi and/or ARB therapy prior Screening 5 . Estimated glomerular filtration rate â‰¥20 &lt; 90 mL/min/1.73 m2 6 . Willingness maintain ACEi and/or ARB therapy , additional antihypertensive therapy control blood pressure , stable dose 7 . Maintenance additional antihypertensive medication , insulin , oral hypoglycemic agent , cholesterollowering medication prior randomization 1 . Female subject pregnant breastfeed 2 . Organ transplant recipient , previous dialysis , nondiabetic renal disease benign cysts anatomical variant 3 . Any history New York Heart Association ( NYHA ) class III/IV heart failure ( HF ) 4 . Screening electrocardiogram show acute , clinically significant finding include limited ST depression 5 . Recent history serious heart problem ( e.g . coronary artery bypass graft , cerebrovascular accident , myocardial infarction ) 6 . History cancer past 5 year , possibly exclude nonmelanomatous skin cancer , localize bladder cancer , situ cervical cancer . 7 . History allergic anaphylactic reaction human , humanize , chimeric murine monoclonal antibody 8 . Participation study investigational drug time Screening AND receipt investigational drug within 42 day prior Screening 9 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5 time upper limit normal 10 . Hemoglobin &lt; 10 g/dL 11 . Positive HIV ( IgG ) antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Type 1 Type 2 diabetes</keyword>
	<keyword>proteinuria</keyword>
</DOC>